BioCentury
ARTICLE | Company News

Celltrion, Hospira avoid biosimilar traffic jam in U.S.

February 24, 2015 2:31 AM UTC

With an FDA advisory committee meeting approaching on March 17 for CT-P13 from Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP), the partners' U.S. interests are aligned thanks to an amended deal that gives Hospira exclusive rights to market the biosimilar of Remicade infliximab in the U.S., Canada and other undisclosed territories.

The situation has been different in Europe, where a co-exclusive agreement allows Hospira and Celltrion each to market the biosimilar under their own brands, which could lead to price competition. CT-P13 was approved in Europe in September 2013. This month, Hospira launched its biosimilar as Inflectra in the EU, where Celltrion will be marketing it as Remsima with the help of distribution partners Mundipharma International Ltd. in some major western European markets and Orion Corp. (HSE:ORNAV; HSE:ORNBV) in Scandinavia. ...